39.45 -0.30 (-0.75%)
After hours: 5:26PM EDT
|Bid||39.45 x 100|
|Ask||39.69 x 100|
|Day's range||38.96 - 44.44|
|52-week range||11.30 - 44.50|
|PE ratio (TTM)||N/A|
|Earnings date||7 May 2018 - 11 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||51.57|
On a day most indexes made gains, Arena Pharmaceuticals skyrocketed following drug trial results and Duluth Holdings fell on a weak forecast for 2018 sales.
Arena Pharmaceuticals Inc. ticked lower Tuesday after the biotech company announced a secondary offering of shares. Arena shares declined 1.9% after hours, following a surge of 29% to close the regular ...
Arena gapped up by nearly a third Tuesday after its ulcerative colitis drug proved strong in a Phase 2 trial.
Shares of Arena Pharmaceuticals Inc. shot up 34% in premarket trade Tuesday, after the drugmaker reported positive results from a phase 2 trial of its treatment for ulcerative colitis. The rally comes ...
Arena rocketed nearly 30% late Monday after its inflammatory bowel disease drug hit each of its goals in a midstage trial.
Arena (ARNA) reports narrower-than-expected Q4 loss. However, revenues decrease year over year. The company is likely to advance ralinepag in phase III study in the second half of 2018.
Arena (ARNA) posted narrower-than-expected loss in the fourth quarter of 2017. However, revenues decreased significantly year over year.
In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64% in local currencies. According to IQVIA, by the end of November 2017, Saxenda accounted for 79%, 86%, 72%, 52%, 47%, 40%, 30%, 19%, 14%, and 6% of the total value of anti-obesity medications sold in the United Arab Emirates, Canada, Denmark, the United States, Italy, Spain, Brazil, Germany, Australia, and Mexico, respectively. In December 2017, Novo Nordisk submitted an application to the FDA seeking an update to Saxenda’s label to include data from the LEADER trial.